I feel bad I made light of the police incident. Just spoke to my wife she's pretty shook up. It is a powerless feeling. This guy has been hawking her for two dogs. Like 16 years. I wish she had whipped her phone out-- he made a false stop and then said just kidding and then Take care of this pretty lady. Accused the driver who we know really well of not wearing his seat belt. I know it's not a huge crime but it's unprofessional as hell and these days it's just not cool to walk up on a Black driver with some bull shit.. I took it too lightly my wife is crying from this. Let this be the record.
I'll tell you what though, I'm getting better at bio-tech. I read so much stuff about what they're doing. It can be a little dry, and in a way its like a different language, but like anything else, just stick with it and force yourself to figure it out. The reason I did, is because I have a new goal. I'm gonna focus on biotechs more. That's where the REAL action is anyway. The time has come. I'm glad to hear this. Use me as a reflecting pool -this sector has been my backbone for 30 years.
ADX-629 Looks promising Van. Their lead compound will have to be broadened to include Dry Eye but that should happen. Good morning, and thank you for taking my questions. So my question is regarding ADX-629, it's an oral version of reproxalap. And my question is even though there are two different administration route, but what is the real route through 629 programs from the odd part is the results so far from reproxalap, and also strategically how do you think about prioritized indications for these two molecules? Thank you. Todd Brady -- President and chief executive officer Thanks for the question, Kelly. And I'm glad you mentioned ADX-629 which we view as a hidden gem in our pipeline. When we started this company many years ago, we were excited about RASP as a target. Not only do reproxalap and ADX-629 which are closely related structurally represent new molecules and not only do those new molecules represent targeting new physiologic mediators of disease but the entire pharmacology is different. From 99% of drugs available today, most of drugs that we take today bind to proteins, receptors, enzymes, cytokines, or they're directly involved in making proteins, such as the case with gene therapy. Most drugs available today affect single targets, a particular receptor, a particular enzyme. Reproxalap in ADX-629 are different and that those drugs target a variety of non-protein that is small molecule inflammatory mediators and therefore we have classified RASP inhibition as a systems-based approach. The challenge with the drugs available today is that inhibiting a single target that is taking a single molecule out of a physiological cascade leads to toxicity – now, I guess driving your car with three tires whereas modifying a system without inhibiting a single target have safety advantages and efficacy advantages. One reason that we believe we have seen the broad-based symptomatic activity of reproxalap in dry eye disease, not just with dry eye score, not with dryness score, not just with ocular discomfort score, not just with burning, not just with stinging but across the board it is due to the fact we believe that reproxalap effects variety of the small molecule mediators of inflammation. So this kind of systems-based approach could have efficacy advantages as well. There is no reason why RASP inhibition should only apply to the eye or the front of the eye which is why in response of Justin's question I mentioned RASP inhibition as it may apply to the retina and systemic diseases. We're really thrilled about ADX-629 and the potential thereof. We are currently testing the drug across different forms of inflammation as by representing more allergic or TH2 type inflammation psoriasis representing more autoimmune or TH1 type inflammation. To your question, Kelly, it's really difficult to prioritize diseases or kinds of inflammation as they relate to treatment with ADX-629 until we see the results of those trials, but I think you can hear in our voices today that we are optimistic given the success of reproxalap as you point out about the prospects of ADX-629. In a way the front of the eye for Aldeyra has been a model of inflammation. I think it's very clear with Invigorate and the success we've had in dry eye disease that reproxalap is active and safe and therefore I think there is considerable read through to, the potential success of ADX-629 and that's why we're so excited about keeping you up to date regarding the phase 2 results later this year. I have not spent a lot of time talking about the RASP retina program, I've mentioned it briefly a few times today. RASP are particularly interesting in retinal diseases for two reasons. The obvious reason is the anti-inflammatory effect of RASP inhibition but the other reason is that RASP are involved in binding to other small molecules, which are in some cases not digested or metabolized by the cells in the retina and therefore lead to the accumulation of retinal aggregates. An example might be a [Inaudible] in dry age-related macular degeneration and related diseases such as Stargardt disease. So, I think that there are at least two good reasons mechanistically to test RASP inhibition in the retina. We're currently preparing for IND submission at some point in the near future. And as I mentioned in my prepared comments, we expect to potentially be in clinical testing with our RASP retina program next year. XXXXX Those data have been positive that the drug has been well-tolerated. That there are no clinically relevant safety signals now in more than 1200 patients that have been exposed to reproxalap -- all is remarkable and we are hoping that our colleagues at the FDA recognize the breadth of activity across two different diseases, as well as the safety advantages I've mentioned of reproxalap in getting this drug in the hands of patients and physicians. Unknown speaker -- Citi -- Analyst OK. Thank you for taking the questions. Todd Brady -- President and chief executive officer Thanks, Kelly. Operator [Operator instructions] Your next question comes from Edwin Zhang of H.C. Wainwright. Your line. Edwin Zhang -- H.C. Wainwright -- Analyst Thanks for taking my questions. First, congrats on the solid quarter. A quick question on international expansion. What's your current thinking on geographical expansion after the recent clinical success of a reproxalap? Are you looking for partners ex-US? Also related to this, does the European regulator accept chamber studies for pivotal trial and the EMA approval in dry eyes and allergic conjunctivitis? Thank you. Todd Brady -- President and chief executive officer A very good morning. And I will say I have enjoyed discussing with you over the years our potential outside of the United States. I think too often biotechnology companies focus only on the United States. I guess that is easy to do given that many biotechnology companies are domiciled exclusively in the United States. But there really is no reason why reproxalap couldn't be a first-line option across the world. Ocular diseases such as allergic conjunctivitis may be even more prevalent outside of the United States, particularly in Asia. I can tell you that as a result of our continued progress in allergic conjunctivitis and dry eye disease, Aldeyra has received a considerable amount of inbound interest regarding at regional partnering outside the United States. The direct answer to your question is yes, we would intend to partner reproxalap outside the United States. Inside of the United States, we have many options. As I've mentioned in other calls one of the attractive elements of ocular surface inflammation is that commercial launches are feasible for small companies generally based on what other companies have done sales forces are in the 100 to 200 to 300 rep range. This is imminently possible for small companies to achieve; however, the question for Aldeyra is what is optimal for reproxalap which, as you know, has broad applicability in allergic conjunctivitis and dry eye disease. So we like any other responsible biotechnology company will continue to evaluate the pros and cons of an internal launch reproxalap versus a partnered launch of reproxalap. Our most recent financing from last week gives the company considerable flexibility to evaluate both a go-it-alone and partnered strategy and we are thrilled to be in such a position of financial strength for obvious reasons. Operator Your next question comes from Esther Hong of Berenberg. Your line is open. Esther Hong -- Berenberg Capital Markets -- Analyst Hi, good morning. I wanted to ask about pipeline candidate ADX-1612 any updates there? It looks like data is going to be releasing about 2022 from an investigator-sponsored study in ovarian cancer. So any expectations and future plans in that indication? Thanks. Todd Brady -- President and chief executive officer Hi, Esther good morning. Thanks for asking about 1612 because we often don't have time to discuss that compound. You're absolutely correct. The 1612 is primarily now the subject of a phase 2 ovarian cancer trial that is being run across multiple centers in Europe in combination with PARP inhibitors. We are not exactly sure of the timing of the results of that trial because that trial is investigator-sponsored as you mentioned. However, I think there is considerable preclinical reason to believe that activity of HSP90 inhibition, which is the mechanism of 1612 in combination with PARP inhibition and potentially platinum therapy could be beneficial for patients. We await the results of those investigations in the ISP and obviously would communicate to the street once we hear back. Prakhar Agrawal -- JonesTrading -- Analyst Yes, so on ADX 629, the phase 2 trial in mild allergen asthma -- given it's the small proof of concept trial with limited treatment duration could you frame expectations on what could we expect to see on various endpoints? And any biomarker data that you will be measuring? Thank you. Todd Brady -- President and chief executive officer Thanks, again for the excellent question. I'm thrilled to receive so many questions on our pipeline. I think too often the street values Aldeyra as a dry eye disease company. Our pipeline, as you know, extends well beyond the two indications that we're moving forward for reproxalap and as we look forward to the future, I think that there will be a lot to say about not only anterior ocular inflammation but also retinal and systemic disease. In terms of asthma specifically, asthma, psoriasis, and COVID-19 are proof of concept of phase 2 clinical trials as you point out not only are clinical endpoints assessed but also biomarker assessment that represents a large portion of the output of those trials. Asthma is particularly interesting not only because it is a TH2 allergic-type inflammation, where we have at least with reproxalap consistently demonstrated activity. But also because of the number of clinical and biomarker endpoints that can be assessed associated with asthma. Two examples are the standard pulmonary function tests associated with most asthma clinical trials and eosinophil sputum accounts, which is a measure of inflammatory cell counts in the sputum of patients. We're also intending to measure plasma cytokine profiles, plasma RASP profiles and I'm really excited to assess all these different data, which will point us to mechanistically appropriate clinical indications in the future for ADX-629. ///////////// Summery- Van bulging eyes can be a problem so can dry eye. My Grandma on 69th street had it. These guys have a nice lead candidate that is sure to make it. Less clear how they partner up aND HOW MUCH MONEY THEY WOULD GET. However the proof of concept here is large and inflammation is inflammation I think the oral ADX-629 might be useful for Covid/ SARS-! But of course I have Atosa who are doing some of the same things through the nose... And opening is an opening I guess.... Looks Like a Good Biotech Company BUY! I will as soon as I free up space.~si
Amazon will open its first robotics fulfillment center in Louisiana Amazon(NASDAQ:AMZN) announces its first robotics fulfillment center in Louisiana. The Shreveport-based, 650,000 square-foot facility will create over 1,000 new full-time jobs. Workers at the facility will pack and ship smaller consumer items like books, toys, and electronics. I wonder if fifty years from now there will be a news story about a workplace shooting done by a robot.
Can they get it right this time? On Next Friday) 12:00 P.M.Veritone(NASDAQ:VERI)holds a virtual investor day and technology expo. The company will discuss new business strategies as well as the overall vision. Experts will demonstrate new technologies publicly for the first time, which has the potential to draw the attention of analysts and re-ratings. Shares of Veritone fell sharply following an investor presentation in March.
Albemarle upgraded at J.P. Morgan as earnings growth view 'conservative' Albemarle(ALB+5.8%)shares recover much of yesterday's 8.2% post-earnings drop, as J.P. Morgan upgrades shares to Neutral from Underweight with a $152 price target, raised from $125, saying the company's full-year outlook "seems conservative." "We view Albemarle's idea of a 30%-40% decrease in Catalyst EBITDA from 2020's trough level as severe, given improvements in miles driven, gasoline demand and crack spreads," JPM analyst Jeffrey Zekauskas writes, adding the company also has a "conservative view" of Bromine operations. Albemarle is "leaving a period of weaker earnings performance and should soon begin a period of greater positive earnings growth," and earnings "should rise sharply in 2022 and 2023 as the company expands capacity in Chile and Australia," according to Zekauskas. Offsetting an anticipated rise in lithium sales, Albemarle said it expects lower EBITDA Y/Y in its Catalysts business and"modestly higher" results in its bromine segment.
Warm.... Warmer..... Hot... BOILING HOT>>>> SEARING ASS HOT!!! Oh I found it, Thank You Alexa... Amazon partners with Tile, rival of Apple's AirTags May 07, 2021 2:23 PM ETAmazon.com, Inc. (AMZN) Late last year, Amazon(NASDAQ:AMZN) rolled out Amazon Sidewalk, a "neighborhood network" that pools the low-frequency, long-range bandwidth in an areato help connected devices operate outside the owner's usual network range. Today,Amazon announces that Tile, maker of Bluetooth-enabled tracking tags, will join Sidewalk on June 14. The tie-up means that compatible Echo devices will be able to extend Tile's network coverage further. Sidewalk will also extend Tile's in-home finding experience with Alexa commands able to make the tagged item ring. Alexa can also say which of multiple Echo devices the sought item is near.
1 yr return on ALDX is over 1000%. Maybe should of found this at $17. That's quite a 1 year return! And not that much happened! ThaT'S what makes Biotech different!
CuriosityStream (NASDAQ:CURI):The U.S streaming service went public only in October, but its share price experienced a wild ride. The stock is now down by nearly 50% from previous all-time highs. The documentary-focused streaming platform already boasts 15 million subscribers and grew revenues by over 100% in 2020. Furthermore, the company guides for another 80% growth in 2021. Considering a market cap of just $650 million and potential revenues of $400 million by 2025, this stock has explosive upside potential in the long run.